620 related articles for article (PubMed ID: 21799891)
21. Short-term pyrrolidine dithiocarbamate administration attenuates cachexia-induced alterations to muscle and liver in ApcMin/+ mice.
Narsale AA; Puppa MJ; Hardee JP; VanderVeen BN; Enos RT; Murphy EA; Carson JA
Oncotarget; 2016 Sep; 7(37):59482-59502. PubMed ID: 27449092
[TBL] [Abstract][Full Text] [Related]
22. Selumetinib Attenuates Skeletal Muscle Wasting in Murine Cachexia Model through ERK Inhibition and AKT Activation.
Quan-Jun Y; Yan H; Yong-Long H; Li-Li W; Jie L; Jin-Lu H; Jin L; Peng-Guo C; Run G; Cheng G
Mol Cancer Ther; 2017 Feb; 16(2):334-343. PubMed ID: 27599525
[TBL] [Abstract][Full Text] [Related]
23. Distinct behaviour of sorafenib in experimental cachexia-inducing tumours: the role of STAT3.
Toledo M; Penna F; Busquets S; López-Soriano FJ; Argilés JM
PLoS One; 2014; 9(12):e113931. PubMed ID: 25436606
[TBL] [Abstract][Full Text] [Related]
24. Sunitinib prevents cachexia and prolongs survival of mice bearing renal cancer by restraining STAT3 and MuRF-1 activation in muscle.
Pretto F; Ghilardi C; Moschetta M; Bassi A; Rovida A; Scarlato V; Talamini L; Fiordaliso F; Bisighini C; Damia G; Bani MR; Piccirillo R; Giavazzi R
Oncotarget; 2015 Feb; 6(5):3043-54. PubMed ID: 25460504
[TBL] [Abstract][Full Text] [Related]
25. Cucurbitacin IIb attenuates cancer cachexia induced skeletal muscle atrophy by regulating the IL-6/STAT3/FoxO signaling pathway.
Wang Y; Sun X; Yang Q; Guo C
Phytother Res; 2023 Aug; 37(8):3380-3393. PubMed ID: 37073890
[TBL] [Abstract][Full Text] [Related]
26. MEF2c-Dependent Downregulation of Myocilin Mediates Cancer-Induced Muscle Wasting and Associates with Cachexia in Patients with Cancer.
Judge SM; Deyhle MR; Neyroud D; Nosacka RL; D'Lugos AC; Cameron ME; Vohra RS; Smuder AJ; Roberts BM; Callaway CS; Underwood PW; Chrzanowski SM; Batra A; Murphy ME; Heaven JD; Walter GA; Trevino JG; Judge AR
Cancer Res; 2020 May; 80(9):1861-1874. PubMed ID: 32132110
[TBL] [Abstract][Full Text] [Related]
27. FoxP1 is a transcriptional repressor associated with cancer cachexia that induces skeletal muscle wasting and weakness.
Neyroud D; Nosacka RL; Callaway CS; Trevino JG; Hu H; Judge SM; Judge AR
J Cachexia Sarcopenia Muscle; 2021 Apr; 12(2):421-442. PubMed ID: 33527776
[TBL] [Abstract][Full Text] [Related]
28. Ursolic acid alleviates cancer cachexia by inhibiting STAT3 signaling pathways in C2C12 myotube and CT26 tumor-bearing mouse model.
Chen L; Chen Y; Wang M; Lai L; Zheng L; Lu H
Eur J Pharmacol; 2024 Apr; 969():176429. PubMed ID: 38423241
[TBL] [Abstract][Full Text] [Related]
29. Sex differences in the relationship of IL-6 signaling to cancer cachexia progression.
Hetzler KL; Hardee JP; Puppa MJ; Narsale AA; Sato S; Davis JM; Carson JA
Biochim Biophys Acta; 2015 May; 1852(5):816-25. PubMed ID: 25555992
[TBL] [Abstract][Full Text] [Related]
30. Skeletal muscle is enriched in hematopoietic stem cells and not inflammatory cells in cachectic mice.
Berardi E; Aulino P; Murfuni I; Toschi A; Padula F; Scicchitano BM; Coletti D; Adamo S
Neurol Res; 2008 Mar; 30(2):160-9. PubMed ID: 18397608
[TBL] [Abstract][Full Text] [Related]
31. Decreased insulin-like growth factor-1 expression in response to mechanical loading is associated with skeletal muscle anabolic resistance in cancer cachexia.
Miyazaki M; Sawada A; Sawamura D; Yoshida S
Growth Horm IGF Res; 2023; 69-70():101536. PubMed ID: 37229943
[TBL] [Abstract][Full Text] [Related]
32. JNK signaling contributes to skeletal muscle wasting and protein turnover in pancreatic cancer cachexia.
Mulder SE; Dasgupta A; King RJ; Abrego J; Attri KS; Murthy D; Shukla SK; Singh PK
Cancer Lett; 2020 Oct; 491():70-77. PubMed ID: 32735910
[TBL] [Abstract][Full Text] [Related]
33. Molecular, cellular and physiological characterization of the cancer cachexia-inducing C26 colon carcinoma in mouse.
Aulino P; Berardi E; Cardillo VM; Rizzuto E; Perniconi B; Ramina C; Padula F; Spugnini EP; Baldi A; Faiola F; Adamo S; Coletti D
BMC Cancer; 2010 Jul; 10():363. PubMed ID: 20615237
[TBL] [Abstract][Full Text] [Related]
34. IL-6 mediated JAK/STAT3 signaling pathway in cancer patients with cachexia.
Eskiler GG; Bezdegumeli E; Ozman Z; Ozkan AD; Bilir C; Kucukakca BN; Ince MN; Men AY; Aktas O; Horoz YE; Akpinar D; Genc I; Kaleli S
Bratisl Lek Listy; 2019; 66(11):819-826. PubMed ID: 31747761
[TBL] [Abstract][Full Text] [Related]
35. Cardiac and skeletal muscles show molecularly distinct responses to cancer cachexia.
Shum AM; Fung DC; Corley SM; McGill MC; Bentley NL; Tan TC; Wilkins MR; Polly P
Physiol Genomics; 2015 Dec; 47(12):588-99. PubMed ID: 26395599
[TBL] [Abstract][Full Text] [Related]
36. An integrative transcriptome study reveals Ddit4/Redd1 as a key regulator of cancer cachexia in rodent models.
Niu M; Li L; Su Z; Wei L; Pu W; Zhao C; Ding Y; Wazir J; Cao W; Song S; Gao Q; Wang H
Cell Death Dis; 2021 Jun; 12(7):652. PubMed ID: 34175899
[TBL] [Abstract][Full Text] [Related]
37. Blockade of the IL-6 trans-signalling/STAT3 axis suppresses cachexia in Kras-induced lung adenocarcinoma.
Miller A; McLeod L; Alhayyani S; Szczepny A; Watkins DN; Chen W; Enriori P; Ferlin W; Ruwanpura S; Jenkins BJ
Oncogene; 2017 May; 36(21):3059-3066. PubMed ID: 27893707
[TBL] [Abstract][Full Text] [Related]
38. C26 cancer-induced muscle wasting is IKKβ-dependent and NF-kappaB-independent.
Cornwell EW; Mirbod A; Wu CL; Kandarian SC; Jackman RW
PLoS One; 2014; 9(1):e87776. PubMed ID: 24489962
[TBL] [Abstract][Full Text] [Related]
39. Skeletal muscle glycoprotein 130's role in Lewis lung carcinoma-induced cachexia.
Puppa MJ; Gao S; Narsale AA; Carson JA
FASEB J; 2014 Feb; 28(2):998-1009. PubMed ID: 24145720
[TBL] [Abstract][Full Text] [Related]
40. Increased thrombin generation in a mouse model of cancer cachexia is partially interleukin-6 dependent.
Reddel CJ; Allen JD; Ehteda A; Taylor R; Chen VM; Curnow JL; Kritharides L; Robertson G
J Thromb Haemost; 2017 Mar; 15(3):477-486. PubMed ID: 28058802
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
